Pharmacopuncture therapy versus usual care for lumbar spinal stenosis: A randomized controlled trial.

Researchers in Korea studied whether pharmacopuncture therapy could help people with lumbar spinal stenosis, a condition where the spinal canal narrows and causes back and leg pain. This condition is becoming more common as populations age, making effective non-surgical treatments increasingly important.

The study included 96 patients who were randomly assigned to receive either pharmacopuncture therapy or usual medical care. Pharmacopuncture involves injecting herbal extracts into specific points on the body, such as acupuncture points or muscles. Patients received treatment twice weekly for 12 weeks and were followed for a full year.

The results showed that pharmacopuncture was significantly more effective than usual care. Patients receiving pharmacopuncture experienced a 2.7-point greater reduction in their dominant pain scores after 13 weeks compared to those receiving conventional treatment. They also showed meaningful improvements in their ability to function in daily activities and overall quality of life. These benefits lasted throughout the entire year-long study period.

Additionally, patients in the pharmacopuncture group recovered faster, with more achieving at least a 50% reduction in pain compared to the usual care group. No serious side effects were reported during the study, suggesting pharmacopuncture is safe when properly administered.

This research supports pharmacopuncture as an effective conservative treatment option for lumbar spinal stenosis, particularly for patients seeking alternatives to surgery or those who haven't responded well to conventional treatments. If you're considering pharmacopuncture for spinal stenosis, consult with a licensed acupuncturist who has specialized training in this technique.

This multicenter, pragmatic randomized controlled trial evaluated pharmacopuncture therapy (PPT) versus usual care (UC) for lumbar spinal stenosis in 96 patients over 53 weeks. Patients received treatment twice weekly for 12 weeks with follow-up assessments at weeks 13, 25, and 53. The primary outcome—change in numeric rating scale (NRS) for dominant pain at week 13—demonstrated a statistically significant 2.7-point greater reduction in the PPT group compared to UC. Secondary outcomes including functional disability and quality of life measures showed significant improvements favoring PPT, with effects sustained through week 53. Survival analysis revealed significantly faster recovery rates (≥50% NRS reduction) in the PPT group. No serious adverse events were reported. The study provides high-quality evidence supporting PPT as a prioritized conservative treatment for LSS, particularly relevant in aging patient populations where this condition is increasingly prevalent.